Dr. Peter W. Mullen, was a tenured member of the Department of Pharmacology at the University of Manchester prior to establishing Kemic Bioresearch. His research interests in pharmacokinetics and toxicology include  nonlinear  kinetics, forensic  toxicokinetics, bioavailability and the effects of immune modulation on drug disposition.  Dr. Mullen is  the founding editor of the International Journal of Immunopharmacology (now, International Immunopharmacology) and a member of many learned socities including the AACT, BPS, CSFS, SPS, SOTC and TIAFT.  He is also a current board member of the Nova Scotia Health Research Foundation.  He has organized several scientific meetings including a NATO Advanced Study Institute and the 1998 Annual Meeting of the Canadian Society of Forensic Science.  Since 1987, Kemic's acclaimed basic pharmacokinetics course has been presented by Dr. Mullen at various venues internationally.

Dr. John R. Carpenter holds degrees in pharmacology from both British (B.Sc, London) and Canadian (Ph.D., Alberta) universities. Currently a freelance medical communications consultant and medical writer, Dr. Carpenter also taught medical, pharmacy and science students at the University of Manchester for 18 years.  In addition to original publications in the scientific literature, Dr. Carpenter has contributed to several texts including Basic Pharmacology (ed. R.W. Foster).  He is also the author of Pharmacology from A to Z and co-author (with Prof. D. Laurence) of A Dictionary of Pharmacology and Allied Topics.

Dr. David W. A. Bourne is an Associate Professor in the College of Pharmacy, University of Oklahoma.  Internationally recognized for his work concerning the mathematical modeling of pharmacokinetic data and the development of related software, Dr. Bourne has also been a consultant in pharmacokinetics to the UN Industrial Development Organization and the pharmaceutical industry.  He has held academic appointments in both Australia and the United States.  He is a member of AAPS and ASCPT  and  currently serves on the Editorial Advisory Board of the Journal of Pharmaceutical Sciences.

Dr. Arthur B. Straughn  is Professor and Director of the Drug Research Laboratory, College of Pharmacy, University of Tennessee, Memphis where he has received several excellence in teaching awards.  Dr. Straughn's teaching, research and over 60 publications are in the areas of bioavailability, pharmacokinetics and assay methodology.  Since 1974 as principal or co- investigator, Dr. Straughn has attracted extramural funding in excess of $10 million  in support of his research from such sources as the National Cancer Institute, the FDA, the Tennessee Dept. of Public Health and Environment and the pharmaceutical industry.

Dr. Russell J. Rackley earned his BS (Pharmacy) and Ph.D. from the University of Tennessee.  Currently, Dr. Rackley is Executive Director, PK/DM at Mylan Pharmaceuticals Inc.  He was formerly director of Biopharmaceutics at Purepac Pharmaceutical Co. following seven years at Ciba-Geigy.   His areas of expertise include in vivo-in vitro correlation  and the use of STELLA for simulation of in vivo performance of oral drug delivery systems. Dr. Rackley is experienced in pharmacokinetic/ pharmacodynamic modeling and simulation and the use of deconvolution/convolution methods.

Dr. Troy W. McCall is curently the Chief Operating Officer at Premier Research Group plc where he is responsible for all aspects of the Group’s worldwide clinical research activities.  Dr. McCall holds a doctorate in pharmaceutical sciences from the University of Tennessee. The holder of patents involving controlled release technology, Dr. McCall's research has focused on improving R&D productivity through the application of pharmacokinetic modeling, in vitro-in vivo correlations and neural networks.  Dr. McCall is a member of the AAPS, CRS and the DIA.